Lipoprotein News and Research

RSS

A lipoprotein is a biochemical assembly that contains both proteins and lipids. The lipids or their derivatives may be covalently or non-covalently bound to the proteins.

Angptl4 protein deficiency could promote inflammatory response in people who consume high saturated fat

A new report in the December Cell Metabolism identifies a protein without which diets high in saturated fat lead to a massive inflammatory response that can prove fatal. The studies in mice suggest that deficiencies in this protective pathway could promote inflammation in those who regularly consume high levels of saturated fat.

1 Dec 2010

Amount of vegetables consumed in childhood correlated to arterial stiffness in adulthood

Eating a lot of fruits and vegetables as a child is associated with healthier arteries as an adult. The amount of vegetables consumed in childhood correlated to the amount of arterial stiffness in adulthood. Children who consistently eat lots of fruits and vegetables lower their risk of having stiff arteries in young adulthood, according to research reported in Circulation: Journal of the American Heart Association.

30 Nov 2010

Amarin reports top-line results from AMR101 Phase 3 trial for treatment of high triglycerides

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from the MARINE study, its first Phase 3 clinical trial of lead drug candidate AMR101.

29 Nov 2010

Neptune, Acasti completes preclinical program comparing CaPre with Lovaza

Neptune Technologies & Bioressources Inc. subsidiary, Acasti Pharma Inc., reports the completion of its preclinical program designed to compare the lipid management effects of Acasti's drug candidate CaPre versus prescription drug Lovaza.

25 Nov 2010

Impax initiates challenge of patents relating to WELCHOL

Impax Laboratories, Inc. today confirms that it has initiated a challenge of patents listed by Daiichi Sankyo, Inc. in connection with its WELCHOL® (Colesevelam HCl) for Oral Suspension, 3.75 gm/packet and 1.875 gm/packet.

22 Nov 2010

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

Anti-cancer drug smuggled using a nanocarrier past protective blood-brain barrier into brain tumours

Scientists in Germany have developed a way of smuggling an anti-cancer drug past the protective blood-brain barrier and into brain tumours and metastases using a nanocarrier - a tiny capsule specially designed to pass through cell membranes and deliver its anti-cancer drug to the cancer cell.

18 Nov 2010

Researchers report results from Phase III DEFINE study for coronary heart disease

Researchers today presented results from the Phase III DEFINE (Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib) study with Merck's investigational CETP inhibitor, anacetrapib. In the trial of 1,623 patients with coronary heart disease (CHD) or CHD risk equivalents, anacetrapib showed no significant differences from placebo in the primary safety measures studied.

18 Nov 2010

BioInvent receives FDA IND clearance for BI-204 Phase II trial in cardiovascular disease

BioInvent International AB today announces IND clearance from the U.S. Food & Drug Administration (FDA) to initiate a Phase II study for BI-204. BI-204 is a human monoclonal antibody that specifically targets oxidized forms of a low-density lipoprotein (LDL) which has been linked to increased inflammatory processes leading to plaque formation in the blood vessel walls. BI-204 is being co-developed with Genentech for secondary prevention of cardiovascular events in patients with acute coronary syndrome (ACS).

10 Nov 2010

CaPre drug candidate effective in managing impaired glucose tolerance

Neptune Technologies & Bioressources Inc. subsidiary Acasti Pharma Inc. reports preclinical results showing that its leading drug candidate CaPre, performed significantly better than the currently marketed drug, Lovaza, at managing impaired glucose tolerance (IGT) a serious pre-diabetic state associated with increased risk of diabetes and heart disease.

4 Nov 2010

Malvern Zetasizer Nano used to characterize environmentally responsive nanoparticles

The rapid, real-time measurement capabilities of the Zetasizer Nano system from Malvern Panalytical have enabled quantified nanoscale characterization of the environmental sensitivity of novel solubilization nanoparticles.

From Malvern Panalytical 28 Oct 2010

Neptune launches Onemia medical food

Neptune Technologies & Bioressources Inc. enters the pharmaceutical market with the launch of Onemia™, the first medical food of Neptune's subsidiary Acasti Pharma Inc.. Only two years since its foundation, Acasti has completed the development and launch of "Onemia™" on October 21, 2010 at the Cardiometabolic Health Congress meeting in Boston.

25 Oct 2010

Essentialis, FDA enter agreement on SPA for DCCR Phase 3 efficacy study in patients with high triglycerides

Essentialis, Inc. announced today that the company has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a Phase 3 efficacy study required for product registration for its product candidate, Diazoxide Choline Controlled Release Tablet (DCCR), for the treatment of patients with very high triglycerides.

25 Oct 2010

New gene therapy product reduces plasma cholesterol levels

Amsterdam Molecular Therapeutics (AMT) Holding N.V. a leader in the development of gene based therapies, today announced that its gene therapy product incorporating siRNA sequences into microRNA scaffolds to silence Apolipoprotein B100 (AAV-miApoB) was able to significantly lower plasma cholesterol levels in vivo over a period of 18 weeks. These preliminary results suggest that this approach could lead to a treatment for high cholesterol in humans

25 Oct 2010

Study finds metabolic syndrome may indicate breast cancer risk in post-menopausal women

Metabolic syndrome, associated with the sedentary lifestyle and energy dense diet of Western industrialized societies, may be an indicator of breast cancer risk in post-menopausal women, according to a new study to be released at the National Italian American Foundation event, "Let's Talk About It: A Spotlight on Women's Health" on October 22nd at the Washington Hilton in Washington, D.C.

25 Oct 2010

Injecting apoA-V protein may reduce high triglyceride levels: Research

Injecting a protein that helps break down triglycerides may someday help treat an inherited form of high triglycerides, according to a new study in Arteriosclerosis, Thrombosis, and Vascular Biology, an American Heart Association journal.

22 Oct 2010

Study: apoA-V may reduce high triglyceride levels, coronary artery disease

An exciting new study conducted by Children's Hospital Oakland Research Institute scientists identified that an injection of the protein apolipoprotein A-V may reduce high triglyceride levels in the blood and subsequently reduce coronary artery disease. Like cholesterol, elevated levels of triglyceride, a fat in the blood, is associated with the increased risk of heart disease—the number one cause of death in the United States.

22 Oct 2010

Neptune second quarter revenue increases 200% to $4,114,000

Neptune Technologies & Bioressources Inc. today reports its consolidated financial results for the three and six-month periods ended August 31, 2010.

15 Oct 2010

Metabolic screening before conception predicts development of diabetes in subsequent pregnancy

Cardio-metabolic risk factors such as high blood sugar and insulin, and low high density lipoprotein cholesterol that are present before pregnancy, predict whether a woman will develop diabetes during a future pregnancy, according to a Kaiser Permanente study in the current issue of the American Journal of Epidemiology.

13 Oct 2010

Essentialis receives patent for active component in DCCR product

Essentialis, Inc. announced today that the United States Patent & Trademark Office (USPTO) has issued U.S. Patent No. 7,799,777 entitled Salts of potassium ATP channel openers and uses thereof. The patent claims a novel composition of a polymorph of diazoxide choline, the active ingredient in the Essentialis lead product, DCCR. Essentialis has successfully completed phase 2b clinical trials with DCCR, showing a highly significant triglyceride reduction in dyslipidemic patients.

12 Oct 2010

Lipoprotein News and Research

Further Reading

Angptl4 protein deficiency could promote inflammatory response in people who consume high saturated fat

Amount of vegetables consumed in childhood correlated to arterial stiffness in adulthood

Amarin reports top-line results from AMR101 Phase 3 trial for treatment of high triglycerides

Neptune, Acasti completes preclinical program comparing CaPre with Lovaza

Impax initiates challenge of patents relating to WELCHOL

VYTORIN reduces major vascular events in patients with chronic kidney disease

Anti-cancer drug smuggled using a nanocarrier past protective blood-brain barrier into brain tumours

Researchers report results from Phase III DEFINE study for coronary heart disease

BioInvent receives FDA IND clearance for BI-204 Phase II trial in cardiovascular disease

CaPre drug candidate effective in managing impaired glucose tolerance

Malvern Zetasizer Nano used to characterize environmentally responsive nanoparticles

Neptune launches Onemia medical food

Essentialis, FDA enter agreement on SPA for DCCR Phase 3 efficacy study in patients with high triglycerides

New gene therapy product reduces plasma cholesterol levels

Study finds metabolic syndrome may indicate breast cancer risk in post-menopausal women

Injecting apoA-V protein may reduce high triglyceride levels: Research

Study: apoA-V may reduce high triglyceride levels, coronary artery disease

Neptune second quarter revenue increases 200% to $4,114,000

Metabolic screening before conception predicts development of diabetes in subsequent pregnancy

Essentialis receives patent for active component in DCCR product

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News